Sugi Predict

Sugi Predict / Targets / AP3D1

AP3D1

AP-3 complex subunit delta-1 · O14617 · AP3D1 on Sugi Atlas →

101 patent compounds predicted against AP3D1, 79 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL22024879 SCHEMBL22024879 0.70 1/20
SCHEMBL4698765 SCHEMBL4698765 0.61 1/20
SCHEMBL4700718 SCHEMBL4700718 0.60 1/20
SCHEMBL4699844 SCHEMBL4699844 0.60 1/20
SCHEMBL2806838 SCHEMBL2806838 0.58 1/20
SCHEMBL14070193 SCHEMBL14070193 0.58 1/20
SCHEMBL4697700 SCHEMBL4697700 0.58 1/20
SCHEMBL21943483 SCHEMBL21943483 0.57 1/20
SCHEMBL14070255 SCHEMBL14070255 0.56 1/20
SCHEMBL4697113 SCHEMBL4697113 0.56 1/20
SCHEMBL4699434 SCHEMBL4699434 0.56 1/20
SCHEMBL14069588 SCHEMBL14069588 0.56 1/20
SCHEMBL20558521 SCHEMBL20558521 0.56 1/20
SCHEMBL4697958 SCHEMBL4697958 0.56 1/20
SCHEMBL4754278 SCHEMBL4754278 0.56 1/20
SCHEMBL14069862 SCHEMBL14069862 0.56 1/20
SCHEMBL14069733 SCHEMBL14069733 0.55 1/20
SCHEMBL29728053 SCHEMBL29728053 0.55 1/20
SCHEMBL4700683 SCHEMBL4700683 0.55 1/20
SCHEMBL4787917 SCHEMBL4787917 0.55 1/20

Clinical trials — most relevant to AP3D1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3ACTIVE_NOT_RECRUITING
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3COMPLETED
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK) PHASE2/PHASE3RECRUITING
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) PHASE1/PHASE2NOT_YET_RECRUITING
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes PHASE2RECRUITING
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
D-aspartate and Therapeutic Exercise EARLY_PHASE1UNKNOWN
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy EARLY_PHASE1RECRUITING
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Susceptibility Genes in Autism Spectrum Disorders nanCOMPLETED
Pigeon Peas (Cajanus Cajan) : a Natural Anti-inflammatory Facilitating Weight Loss in Obese Patients Returning to Sport? nanUNKNOWN
Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients nanRECRUITING
Weight Variation on Cop nanCOMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Circulating Markers for Ischemic Heart Disease nanRECRUITING
Study of the Genetic Factors Involved in Autism and Related Disorders nanRECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions nanRECRUITING
A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS nanNOT_YET_RECRUITING
Biomarkers of CASH nanACTIVE_NOT_RECRUITING
Apelin12 in Acne Vulgaris nanUNKNOWN
Clinical and Genetic Study of Autism Spectrum Disorder nanCOMPLETED
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients nanCOMPLETED
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a AP3D1 binder may also engage these)

ProteinNameSimilarity
O54774 — 1.000 O54774 →
Q865S1 — 1.000 Q865S1 →
P54362 — 0.998 P54362 →
PPP2R5D Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform 0.997 landscape →
Q28653 — 0.996 Q28653 →
Q9W3E1 — 0.994 Q9W3E1 →
Q7Z3E5 — 0.994 Q7Z3E5 →
Q9UTL8 — 0.993 Q9UTL8 →
Q2KI89 — 0.993 Q2KI89 →
Q8L7A9 — 0.993 Q8L7A9 →
A1A535 — 0.992 A1A535 →
Q86T65 — 0.992 Q86T65 →
A0JMA8 — 0.992 A0JMA8 →
Q84K16 — 0.992 Q84K16 →
Q5R629 — 0.992 Q5R629 →
Q99NB9 — 0.992 Q99NB9 →
O43150 — 0.991 O43150 →
Q9Y103 — 0.991 Q9Y103 →
Q3UMY5 — 0.991 Q3UMY5 →
NFKB1 Nuclear factor NF-kappa-B p105 subunit 0.991 landscape →
Q9ZUI6 — 0.991 Q9ZUI6 →
P36000 — 0.991 P36000 →
Q5U2Y6 — 0.991 Q5U2Y6 →
P70600 — 0.991 P70600 →
Q29RR5 — 0.991 Q29RR5 →
Q9QZE5 — 0.991 Q9QZE5 →
A1XD95 — 0.991 A1XD95 →
A1XD94 — 0.991 A1XD94 →
PPP2R5A Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit alpha isoform 0.991 landscape →
Q6PD03 — 0.991 Q6PD03 →